Added to YB: 2025-08-11
Pitch date: 2025-08-07
NVO [bullish]
Novo Nordisk A/S
+1.68%
current return
Author Info
Summit Stocks shares weekly in-depth articles on the best stocks and insights into their portfolio. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 315.86
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk's Q2 Doesn't Change My View
NVO: Down 67% YOY, stock drops 5% on earnings. Q2 revenue +13% YOY to 77B DKK, but slowing vs Q1's 20%. Op profit +25% to 72B DKK (47% margin). Obesity sales +36% US, +125% IO with Wegovy +335% IO. 900M global obesity opportunity (<1% treated). Illegal compounding hurting US sales (1M patients). Long-term price cuts likely as market expands.
Read full article (3 min)